Samenvatting

Samenvatting keuzevak psychopharmacology (17/20 eerste zit)

2 keer verkocht

Vak
Psychopharmacology

Instelling
Thomas More Hogeschool (tmhs)

Volledige en uitgebreide samenvatting van het keuzevak psychopharmacology. De samenvatting is het in Engels, aangezien het vak ook in het Engels gegeven wordt. Dingen die moeilijk uitgelegd werden, heb ik er in het Nederlands bijgezet. Lastig vak met veel leerstof, maar als je op tijd begint met ...

[Meer zien]

Voorbeeld 4 van de 141 pagina's

Bekijk voorbeeld

Geupload op 27 september 2023
Aantal pagina's 141
Geschreven in 2022/2023
Type Samenvatting

ancient history
influences psychiatry
behavioral neuroscience
pharmacokinetics
pharmacodynamics
preclinical research
animal research
clinical research
therapy adherence
substance
substance use disorde

Volgen

nelethys Lid sinds 3 jaar 44 documenten verkocht

€6,49

In winkelwagen

Opslaan

100% tevredenheidsgarantie
Direct beschikbaar na je betaling
Lees online óf als PDF
Geen vaste maandelijkse kosten

2022-2023

PSYCHOPHARMACOLOGY
Gedoceerd door Sam Willems

,Inhoudsopgave
1. Ancient history ............................................................................................................................................. 5
1.1. Charvet (18th-19th century) .......................................................................................................................... 5
1.2. Moreau de Tours (19th century) .................................................................................................................. 6
1.3. Mantegazza ................................................................................................................................................. 6

2. Influences from Psychology .......................................................................................................................... 7
2.1. Experimental Psychology ............................................................................................................................. 7
2.1.1. Kraeplin ................................................................................................................................................ 8
2.1.2. Rivers ................................................................................................................................................... 8
2.1.3. Hollingworth ........................................................................................................................................ 9
2.1.4. Delaberre and Scripture ...................................................................................................................... 9
- first psychological study on effects of cannabis on consciousness and someone’s motivational will .............. 9
2.2. Biology & comparative psychology = behavioral psychology ...................................................................... 9
2.2.1. Classical Conditioning ........................................................................................................................ 10
2.2.2. Operant Conditioning ........................................................................................................................ 10
2.3. Behavioral pharmacology.......................................................................................................................... 11
2.4. Biological Psychology anc Psychopharmacology ....................................................................................... 12
2.5. Example: Hebbian Learning ....................................................................................................................... 12
2.5.1. Classical condition and hebbian learning explained .......................................................................... 13
2.5.2. Placebo effect explained ................................................................................................................... 14
2.5.3. Application: Placebo-controlled dose reduction (PCDR) .................................................................. 15

3. Influences from Psychiatry ......................................................................................................................... 17
3.1. Early pharmacotherapy (1860-1930: before WOII) ................................................................................... 17
3.1.1. Social background .............................................................................................................................. 17
3.1.2. Therapeutic options for the incurable ............................................................................................... 18
3.2. Experimenting with hallucinogenics (1880 - 1940).................................................................................... 19
3.2.1. Accidental discovery of LSD (1938) .................................................................................................... 20
3.2.2. Applications and the public of LSD (post-WO II)................................................................................ 20
3.2.3. How does LSD work and how is it related to Psychotic Episodes? .................................................... 21
3.2.4. Hallucinogenic experiments .............................................................................................................. 22
3.3. The first antidepressant (1930-1950: during WOII) ................................................................................... 22
3.3.1. Social background .............................................................................................................................. 22
3.3.2. Benzedrine®: The uplifting nasal decongestant ................................................................................ 23
3.3.3. Conquering depression during the heydays of the 20th century ...................................................... 23
3.4. The revolutionary decade (post WW II): ANTIPSYCHOTICS ....................................................................... 24
3.4.1. Social background .............................................................................................................................. 24
3.4.2. Phenothiazines (heel goed kennen) .................................................................................................. 25
3.5. The revolutionary decade (post WW II): ANTIDEPRESSANTS .................................................................... 26
3.6. The revolutionary decade: ANXIOLYTICS .................................................................................................. 27
3.7. The revolutionary decade (post WW II): ANTIMANIC DRUGS ................................................................... 27
3.8. In conclusion .............................................................................................................................................. 28

1. Key concepts of Behavioral Neuroscience .................................................................................................. 29
1.1. Anatomy & Organization of the Nervous System ...................................................................................... 30

1

, 1.1.1. Different nervous systems ................................................................................................................. 31
1.1.2. Central nervous system ..................................................................................................................... 32
1.1.3. The deep brain structures ................................................................................................................. 33
1.1.4. What are cells made of? Including neurons ...................................................................................... 33
1.2. Origin of Signal .......................................................................................................................................... 38
1.3. Neural Communication (zie gedragsneuro) ............................................................................................... 39
1.3.1. Communication within a neuron ........................................................................................................... 40
1.3.1.1. Membrane Potentials ..................................................................................................................... 40
1.3.2. Action potential (zie gedragsneuro) .................................................................................................. 43
1.4. Communication between neurons ............................................................................................................ 45
1.4.1. Synaptic communication ................................................................................................................... 45
1.5. Endocrinergic Communication ................................................................................................................... 51
1.5.1. Subtle differences .............................................................................................................................. 52
1.5.1.1. Endocrinergic neurons .................................................................................................................... 52
1.5.1.2. Endocrinergic glands (specialized structures in our body) ............................................................. 53

2. Principles of psychopharmacology: general framework ............................................................................. 55

3. Key concepts of Psychopharmacology: Pharmacokinetics .......................................................................... 57
3.1. Routes of administration ........................................................................................................................... 57
3.2. Absorption & distribution .......................................................................................................................... 62
3.2.1. Partition coefficient is too high ......................................................................................................... 64
3.2.2. Partition coefficient is moderate drug .............................................................................................. 64
3.2.3. Partition coefficient is too low........................................................................................................... 65
3.3. Depot binding (niet heel erg in detail kennen) .......................................................................................... 68
3.4. Inactivation & biotransformation .............................................................................................................. 69
3.5. Excretion .................................................................................................................................................... 72
3.6. Pharmacokinetics: summarize ................................................................................................................... 73

4. Key concepts of Psychopharmacology: Pharmacodynamics ....................................................................... 74
4.1. CNS-Behavioral Categorization of Drugs ................................................................................................... 74
4.2. From synaptic activity… ............................................................................................................................. 75
4.2.1. Drugs as ligands ................................................................................................................................. 76
4.2.3. Dynamic reactions: downregulation and upregulation ..................................................................... 81
4.3. … To behavioral effects .............................................................................................................................. 83
4.3.1. From a drug action to a drug effect ................................................................................................... 83
4.3.2. Dose Response Curves (DRCs) ........................................................................................................... 83
4.3.4. Tolerance ⬄ sensitization ................................................................................................................. 84
4.3.5. Kinetics and dynamics interact with each other ................................................................................ 85

1. Preclinical research .................................................................................................................................... 87
1.1. Animal research and ethics....................................................................................................................... 88
1.1.1. The challenge of testing with animals: .............................................................................................. 89
1.1.2. Focus on construct validity ................................................................................................................ 89
1.1.3. Other quality checks: ......................................................................................................................... 89
1.2. How do we study psychiatric disorders in rodents? ................................................................................... 90
1.3. Example of an animal model ..................................................................................................................... 90
1.4. The 3 R’ and moral principles: research with animals requires moral guidelines ...................................... 92

2

, 2. Clinical research ......................................................................................................................................... 93
2.1. Methodological issues ............................................................................................................................... 94
2.2. Post-marketing research, phase IV ............................................................................................................ 98
2.2.1. FDA/FAGG assessment ...................................................................................................................... 98
2.2.2. Increased regulations = increased costs: discussion ......................................................................... 99
2.3. INCB – International Narcotics Control Board ........................................................................................... 99
After a drug has been approved by the FDA: Phase IV ................................................................................... 102

1. Therapy (non)adherence .......................................................................................................................... 104
1.1. Defining therapy (non)adherence ............................................................................................................ 104
1.2. Factors related to therapy (non)adherence ............................................................................................. 105
1.3. societal problems related to therapy (non)adherence ............................................................................ 109
1.3.1. Social biases ..................................................................................................................................... 109

2. The case of Scott Martin: introduction + instructions ............................................................................... 111
4.1. Getting to know Scott .............................................................................................................................. 111
4.2. Treatment adherence: a new hope ......................................................................................................... 111
4.3. The short-term effects of Lithium ............................................................................................................ 111
4.4. The 6-week follow-up .............................................................................................................................. 112
4.5. Putting strain on Scott’s treatment adherence ....................................................................................... 112
4.6. Remarkable effects come in small packages ........................................................................................... 112

3. How to improve Therapy Adherence ........................................................................................................ 112

1. .................................................................................................................................................................. 114
1.1. Defining substance use disorder .............................................................................................................. 114
1.1.1 Different degrees of substance use disorder.................................................................................... 114

2. What’s in a name ..................................................................................................................................... 115
2.1. Dependency ............................................................................................................................................. 115
2.2. Addiction ................................................................................................................................................. 116
2.3. Abuse ....................................................................................................................................................... 116
2.4. Substance induced disorders or SIDs ....................................................................................................... 116
2.5. "Behavioural addictions" ......................................................................................................................... 117

3. Biopsychosocial mechanisms of SUD ........................................................................................................ 118
3.1. The mesolimbic pathway - The reward system ....................................................................................... 118
3.2. The neurobiology of tolerance and withdrawal ...................................................................................... 119
3.3. Hebbian learning ..................................................................................................................................... 120
3.4. Homeostatis and opponent Proces Theory .............................................................................................. 121
3.5. Evaluation in cravings.............................................................................................................................. 122
3.6. The social network hypothesis ................................................................................................................. 123

4. Treatment strategies of SUDs ................................................................................................................... 123

3

Dit zijn jouw voordelen als je samenvattingen koopt bij Stuvia:

Bewezen kwaliteit door reviews

Studenten hebben al meer dan 850.000 samenvattingen beoordeeld. Zo weet jij zeker dat je de beste keuze maakt!

In een paar klikken geregeld

Geen gedoe — betaal gewoon eenmalig met iDeal, Bancontact of creditcard en je bent klaar. Geen abonnement nodig.

Focus op de essentie

Studenten maken samenvattingen voor studenten. Dat betekent: actuele inhoud waar jij écht wat aan hebt. Geen overbodige details!

Veelgestelde vragen

Wat krijg ik als ik dit document koop?

Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.

Tevredenheidsgarantie: hoe werkt dat?

Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.